First look: Guide your compound design strategy with new visual, industry-leading affinity predictions
Accurate predictions of binding affinity are the holy grail of early-phase discovery, enabling teams to significantly reduce the synthesis and…
Watch industry leaders from Novartis, Apollo Therapeutics and Eikon Therapeutics as they discuss their highs and lows, experience and advice, on running a successful drug discovery team.
Our speakers include Hilary Beck, VP, Head of Chemistry at Eikon Therapeutics, Dean Phillips, Director at Novartis, and Susanne Wright, Director, Chemistry Research and Operations at Apollo Therapeutics.
If you’re interested in the skills needed across successful teams, strategies for communication, collaboration and leadership, or hearing personal anecdotes from leading figures in the field, catch-up the discussion of this insightful panel.
More webinars
StarDrop 8 Is Here: Pioneering Collaboration in Drug Discovery
Science shouldn’t be a solo act. And now, with StarDrop 8 available and ready to use, it never has to be. Learn how you…
Building better QSAR models: A new framework for consistent performance across diverse prediction tasks
Accurate QSAR models lead to more efficient and cost-effective molecular discovery. Better predictions enable you to prioritise the optimal compounds…
